118 related articles for article (PubMed ID: 28868993)
1. STAKEHOLDER INVOLVEMENT THROUGHOUT HEALTH TECHNOLOGY ASSESSMENT: AN EXAMPLE FROM PALLIATIVE CARE.
Brereton L; Wahlster P; Mozygemba K; Lysdahl KB; Burns J; Polus S; Tummers M; Refolo P; Sacchini D; Leppert W; Chilcott J; Ingleton C; Gardiner C; Goyder E
Int J Technol Assess Health Care; 2017 Jan; 33(5):552-561. PubMed ID: 28868993
[TBL] [Abstract][Full Text] [Related]
2. A health technology assessment of COVID-19 vaccination for Nigerian decision-makers: Identifying stakeholders and pathways to support evidence uptake.
Uzochukwu BSC; Okeke C; Shuaib F; Torres-Rueda S; Vassall A; Jit M; Nonvignon J; Uzochukwu AC; Ruiz F
Health Res Policy Syst; 2024 Jun; 22(1):73. PubMed ID: 38926716
[TBL] [Abstract][Full Text] [Related]
3. A situational and stakeholder analysis of health technology assessment in Zimbabwe.
Dzingirai B; Dambiko P; Matyanga C; Manyau P; Tagwireyi D; Postma MJ; Mafirakureva N; van Hulst M
Int J Technol Assess Health Care; 2024 Apr; 40(1):e27. PubMed ID: 38679461
[TBL] [Abstract][Full Text] [Related]
4. Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA.
Janssens R; Russo S; van Overbeeke E; Whichello C; Harding S; Kübler J; Juhaeri J; Bywall KS; Comanescu A; Hueber A; Englbrecht M; Nikolenko N; Pravettoni G; Simoens S; Stevens H; Hermann R; Levitan B; Cleemput I; de Bekker-Grob E; Veldwijk J; Huys I
Patient; 2019 Oct; 12(5):513-526. PubMed ID: 31222436
[TBL] [Abstract][Full Text] [Related]
5. 'The problem is small enough, the problem is big enough': a qualitative study of health technology assessment and public policy on drug funding decisions for children.
Denburg AE; Giacomini M; Ungar WJ; Abelson J
Int J Equity Health; 2020 Mar; 19(1):45. PubMed ID: 32228588
[TBL] [Abstract][Full Text] [Related]
6. Stakeholders' Involvement in Health Technology Assessment in Kazakhstan, Poland and Bulgaria.
Kulembekova L; Hailey D; Kulzhanov M; Tabarov A; Georgiev S; Jaworzynska M; Yanakieva AY; Kosherbayeva L
Patient Prefer Adherence; 2024; 18():1009-1015. PubMed ID: 38798950
[TBL] [Abstract][Full Text] [Related]
7. Using social media research in health technology assessment: stakeholder perspectives and scoping review.
Holtorf AP; Danyliv A; Huang LY; Venable Y; Hanna A; Krause A; Pierre M; Walsh D; Silveira Silva A; Lee SH; Mattingly TJ
Int J Technol Assess Health Care; 2023 Sep; 39(1):e63. PubMed ID: 37732455
[TBL] [Abstract][Full Text] [Related]
8. Involving patients in HTA activities at local level: a study protocol based on the collaboration between researchers and knowledge users.
Gagnon MP; Gagnon J; St-Pierre M; Gauvin FP; Piron F; Rhainds M; Coulombe M; Lepage-Savary D; Desmartis M; Tantchou Dipankui M; Légaré F
BMC Health Serv Res; 2012 Jan; 12():14. PubMed ID: 22248231
[TBL] [Abstract][Full Text] [Related]
9. Assessing medical devices: a qualitative study from the validate perspective.
Bloemen B; Oortwijn W
Int J Technol Assess Health Care; 2024 Apr; 40(1):e29. PubMed ID: 38654522
[TBL] [Abstract][Full Text] [Related]
10. HTA community perspectives on the use of patient preference information: lessons learned from a survey with members of HTA bodies.
Hiligsmann M; Liden B; Beaudart C; Germeni E; Hanna A; Joshi M; Koola CP; Stein B; Tonkinson M; Marshall D; Fifer S
Int J Technol Assess Health Care; 2024 Mar; 40(1):e17. PubMed ID: 38439624
[TBL] [Abstract][Full Text] [Related]
11. Key stakeholders' perspectives: A gap analysis of hospital-acquired pressure injuries.
Riley BH; Pittman J; Otts JAA; Mulekar MS
J Nurs Scholarsh; 2024 Mar; 56(2):291-313. PubMed ID: 37984994
[TBL] [Abstract][Full Text] [Related]
12. An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators.
Desmet T; Julian E; Van Dyck W; Huys I; Simoens S; Giuliani R; Toumi M; Dierks C; Dierks J; Cardone A; Houÿez F; Pavlovic M; Berntgen M; Mol P; Schiel A; Goettsch W; Gianfrate F; Capri S; Ryan J; Ducournau P; Solà-Morales O; Ruof J
J Mark Access Health Policy; 2024 Mar; 12(1):21-34. PubMed ID: 38544972
[TBL] [Abstract][Full Text] [Related]
13. Assessing the Value of Provider-Facing Digital Health Technologies Used in Chronic Disease Management: Toward a Value Framework Based on Multistakeholder Perceptions.
Main C; Haig M; Chavez D; Kanavos P
Med Decis Making; 2024 Jan; 44(1):28-41. PubMed ID: 37882333
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models.
Grimm SE; Pouwels X; Ramaekers BLT; Wijnen B; Knies S; Grutters J; Joore MA
Pharmacoeconomics; 2020 Feb; 38(2):205-216. PubMed ID: 31709496
[TBL] [Abstract][Full Text] [Related]
15. Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review.
Janssens R; Huys I; van Overbeeke E; Whichello C; Harding S; Kübler J; Juhaeri J; Ciaglia A; Simoens S; Stevens H; Smith M; Levitan B; Cleemput I; de Bekker-Grob E; Veldwijk J
BMC Med Inform Decis Mak; 2019 Oct; 19(1):189. PubMed ID: 31585538
[TBL] [Abstract][Full Text] [Related]
16. Is it the Right Topic? An Overlooked Stage in the Institutionalization of Health Technology Assessment.
Peacocke EF; Heupink LF; Ananthakrishnan A; Frønsdal KB
Health Syst Reform; 2023 Dec; 9(3):2329082. PubMed ID: 38715190
[TBL] [Abstract][Full Text] [Related]
17. Barriers and Facilitators of Using R for Decision Analytic Modeling in Health Technology Assessment: Focus Group Results.
Marks Y; Hoch JS; Heath A; Pechlivanoglou P
Pharmacoeconomics; 2024 Jul; 42(7):783-795. PubMed ID: 38607519
[TBL] [Abstract][Full Text] [Related]
18. Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives.
van Overbeeke E; Forrester V; Simoens S; Huys I
Patient; 2021 Jan; 14(1):119-128. PubMed ID: 32856278
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for the Implementation of Hospital Based HTA in Poland: Lessons Learned From International Experience.
Gałązka-Sobotka M; Kowalska-Bobko I; Lach K; Mela A; Furman M; Lipska I
Front Pharmacol; 2020; 11():594644. PubMed ID: 34054508
[No Abstract] [Full Text] [Related]
20. Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis.
Angelis A; Thursz M; Ratziu V; O'Brien A; Serfaty L; Canbay A; Schiefke I; Costa JBE; Lecomte P; Kanavos P
Med Decis Making; 2020 Aug; 40(6):830-845. PubMed ID: 32845234
[No Abstract] [Full Text] [Related]
[Next] [New Search]
